STEREOTACTIC BODY VERSUS CONVENTIONAL FRACTIONATION EXTERNAL BEAM RADIOTHERAPY (EBRT) BOOST FOR HIGH-RISK PROSTATE CANCER (HR-PC); EARLY RESULTS OF PBS: A PHASE II RANDOMIZED TRIAL (NCT03380806)

被引：0
|
作者：
Gouveia, Andre [1 ]
Mesci, Aruz [2 ]
Isfahanian, Naghmeh [1 ]
Dayes, Ian [1 ]
Schnarr, Kara Lynne [1 ]
Quan, Kimmen [1 ]
Maharaj, Lindsay [3 ]
Cuthbert, David [4 ]
Hallock, Abhiram [4 ]
Douvi, Georgia [1 ]
Lukka, Himu [1 ]
Goldberg, Mira [1 ]
Wright, Jim [1 ]
Swaminath, Anand [1 ]
Chow, Tom [5 ]
Diamond, Kevin [4 ]
Ewusie, Joycelyne [6 ]
Hajdok, George [4 ]
Tsakiridis, Theodoros [1 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Hamilton Hlth Sci, Hamilton, ON, Canada
[4] Walker Family Canc Ctr, St Catharines, ON, Canada
[5] Juravinski Canc Ctr, Hamilton, ON, Canada
[6] St Josephs Hlth Care, Hamilton, ON, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 198卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
23
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 34 条
  • [21] Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300
    Marvaso, Giulia
    Vischioni, Barbara
    Pepa, Matteo
    Zaffaroni, Mattia
    Volpe, Stefania
    Patti, Filippo
    Bellerba, Federica
    Gandini, Sara
    Comi, Stefania
    Corrao, Giulia
    Zerini, Dario
    Augugliaro, Matteo
    Fodor, Cristiana
    Russo, Stefania
    Molinelli, Silvia
    Ciocca, Mario
    Ricotti, Rosalinda
    Valvo, Francesca
    Giandini, Tommaso
    Avuzzi, Barbara
    Valdagni, Riccardo
    De Cobelli, Ottavio
    Cattani, Federica
    Orlandi, Ester
    Jereczek-Fossa, Barbara Alicja
    Orecchia, Roberto
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial
    Zapatero, Almudena
    Castro, Pablo
    Roch, Maria
    Carnero, Pablo Rodriguez
    Carroceda, Sara
    Rosciupchin, Alexandra Elena Stoica
    Hernandez, Sergio Honorato
    Cogorno, Leopoldo
    Iturriaga, Alfonso Gomez
    Garcia, David Buchser
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [23] A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy (RT) for intermediate and high-risk prostate cancer (PC): Quality-of-life results (QoL) in SPCG-13 trial
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Hjalm-Eriksson, Marie
    Thellenberg-Karlsson, Camilla
    Astrom, Lennart
    Franzen, Lars
    Fransson, Ann-Sofie
    Leskinen, Markku J.
    Huttunen, Teppo
    Ginman, Claes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Timing of high-dose rate brachytherapy with external beam radiotherapy in intermediate and high-risk localized prostate cancer (THEPCA) patients and its effects on toxicity and quality of life: Results of a randomized feasibility trial.
    Ahmed, Imtiaz
    Thomas, Sharon Shibu
    Cain, Alexander
    Zhang, Jufen
    Palvai, Sreekanth
    Dawam, Dabden
    Veetil, Rakesh Kizhakke
    Romero, Lavinia
    Hayden, Karen
    Choudhury, Mahbuba
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.
    Poon, Darren M. C.
    Lam, Daisy
    Wong, Kenneth C. W.
    Chu, C. M.
    Mo, Frankie
    Suen, Joyce
    Ng, Chi-Fai
    Chan, Anthony T. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [26] ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.
    Francolini, Giulio
    Detti, Beatrice
    Di Cataldo, Vanessa
    Caini, Saverio
    Alitto, Anna Rita
    Parisi, Silvana
    Demofonti, Chiara
    Bruni, Alessio
    Ingrosso, Gianluca
    Timon, Giorgia
    Allegra, Andrea
    Aquilano, Michele
    Ciccone, Lucia Pia
    Salvestrini, Viola
    Frosini, Giulio
    Cerbai, Cecilia
    Desideri, Isacco
    Meattini, Icro
    Mangoni, Monica
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [27] Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
    Kim, Yeon Joo
    Ahn, Hanjong
    Kim, Choung-Soo
    Lee, Jae-Lyun
    Kim, Young Seok
    TRIALS, 2018, 19
  • [28] NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
    Zumsteg, Z.
    Karrison, T.
    Michaelson, M. D.
    Tran, P.
    Kudchadker, R.
    Feng, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S546 - S546
  • [29] Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
    Yeon Joo Kim
    Hanjong Ahn
    Choung-Soo Kim
    Jae-Lyun Lee
    Young Seok Kim
    Trials, 19
  • [30] ACUTE AND SUBACUTE GASTROINTESTINAL AND GENITOURINARY TOXICITY PROFILES OF METFORMIN VERSUS PLACEBO PLUS PROSTATE AND PELVIC RADIOTHERAPY FOR THE MANAGEMENT OF HIGH RISK PROSTATE CANCER: INTERIM TOXICITY RESULTS OF A DOUBLE-BLINDED, MULTICENTRE, PHASE II RANDOMIZED CONTROLLED TRIAL
    McDonald, Megan O.
    Usmani, Nawaid
    Ong, Aldrich
    Koul, Rashmi
    Dubey, Arbind
    Ahmed, Shahida
    Quon, Harvey
    Yee, Don
    Parliament, Matthew
    Sivananthan, Gokulan
    Danielson, Brita
    Rowe, Lindsay
    Rose, James
    Hunter, William
    Sanghera, Karan Paul
    Ghosh, Sunita
    Kim, Julian O.
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S4 - S5
1234